Top Page
SSY Group
(OTC:2005)
SSY Group (2005) vs. iShares MSCI Hong Kong ETF (EWH)
SSY Group Business Overview & Revenue Model
SSY Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.58B | 5.77B | 6.46B | 6.43B | 5.36B | 4.26B |
| Gross Profit | 1.96B | 2.91B | 3.62B | 3.44B | 3.04B | 2.58B |
| EBITDA | 1.25B | 1.74B | 2.11B | 1.86B | 1.40B | 1.09B |
| Net Income | 658.92M | 1.06B | 1.32B | 1.12B | 785.53M | 611.97M |
Balance Sheet | ||||||
| Total Assets | 12.79B | 12.60B | 11.97B | 10.97B | 10.71B | 9.25B |
| Cash, Cash Equivalents and Short-Term Investments | 1.52B | 1.29B | 1.62B | 1.71B | 1.70B | 1.51B |
| Total Debt | 4.02B | 3.64B | 3.37B | 3.21B | 3.11B | 2.44B |
| Total Liabilities | 5.19B | 5.07B | 4.70B | 4.42B | 4.22B | 3.34B |
| Stockholders Equity | 7.27B | 7.22B | 6.93B | 6.21B | 6.22B | 5.65B |
Cash Flow | ||||||
| Free Cash Flow | 94.40M | -49.39M | 221.88M | 368.70M | 359.58M | 236.61M |
| Operating Cash Flow | 381.69M | 491.03M | 925.75M | 786.82M | 747.91M | 527.64M |
| Investing Cash Flow | -354.67M | -521.76M | -640.19M | -402.72M | -681.23M | -287.58M |
| Financing Cash Flow | -234.64M | -295.42M | -304.57M | -190.51M | 136.13M | 366.35M |
SSY Group Technical Analysis
SSY Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$8.82B | 13.40 | 9.12% | 4.85% | -29.18% | -51.49% | |
73 Outperform | HK$6.21B | 6.96 | 10.85% | 6.14% | -20.64% | -25.39% | |
72 Outperform | HK$12.32B | 11.52 | 25.92% | 4.24% | 19.05% | 13.68% | |
72 Outperform | HK$1.82B | 9.55 | 5.34% | 5.21% | 2.89% | -68.83% | |
70 Outperform | HK$10.06B | 11.41 | 7.48% | 4.39% | 1.65% | -16.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$12.22B | -137.89 | -1.87% | 0.83% | 19.21% | -115.91% |
SSY Group Corporate Events
SSY Group Limited has announced that its product, Finerenone, has received approval from the National Medical Products Administration of China for registration as a bulk drug for market preparations. This approval marks the second such endorsement for entities within China, highlighting the company’s progress in expanding its pharmaceutical offerings. Finerenone is designed to aid adult patients with chronic kidney disease linked to type 2 diabetes, aiming to mitigate risks such as a decline in kidney function, end-stage renal disease, cardiovascular death, and heart failure hospitalization. This development is expected to enhance SSY Group’s market position and provide significant benefits to patients and stakeholders.
SSY Group Limited has announced that its products, Bilastine and Sodium Picosulfate, have received approval from the National Medical Products Administration of China for market preparation as bulk drugs. This development is significant for the company as it enhances its product offerings in the pharmaceutical market, potentially strengthening its position and providing new opportunities for growth.
SSY Group Limited has announced that it received approval from the National Medical Products Administration of China for the production and registration of Tolterodine Tartrate Sustained-release Capsules, a treatment for overactive bladder. This approval marks the third such recognition for SSY Group among PRC entities, potentially enhancing its market position and offering new opportunities for growth in the pharmaceutical sector.
SSY Group Limited announced that its Vitamin A Palmitate has received approval from the National Medical Products Administration of China, allowing it to be marketed as a bulk drug for vitamin supplement injections. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing new opportunities for growth in the pharmaceutical sector.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of several drugs, including Aminophylline Tablets, Procaterol Hydrochloride Inhalation Solution, and Ademetionine 1,4-Butanedisulfonate for Injection. These approvals signify the company’s progress in expanding its product offerings in the treatment of respiratory and liver conditions, potentially enhancing its market position and providing new treatment options for patients.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Indobufen Tablets, a type 3 chemical drug. This development marks a significant step in the company’s product offerings, particularly in the treatment and prevention of ischemic cardiovascular and cerebrovascular diseases, as well as thrombosis during hemodialysis. The approval enhances SSY Group’s position in the pharmaceutical market, potentially benefiting shareholders and investors by expanding its product portfolio and market reach.
SSY Group Limited has announced that its Lincomycin Hydrochloride Injection has passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs by the National Medical Products Administration of China. This development is significant as it enhances the company’s product portfolio and strengthens its position in the pharmaceutical market, particularly for patients who cannot use penicillin for severe infections.
SSY Group Limited has announced the approval of three bulk drugs—Fenofibrate, Choline Fenofibrate, and Levornidazole Disodium Phosphate—by China’s National Medical Products Administration. These approvals enhance the company’s product offerings in the treatment of hyperlipidemia, hypercholesterolemia, and severe infections, potentially strengthening its market position and benefiting stakeholders by expanding its portfolio in the Chinese pharmaceutical market.
SSY Group Limited has announced that its Vitamin B6 Injection has received approval from the National Medical Products Administration of China for the Consistency Evaluation of the Quality and Efficacy of Generic Drugs. This development signifies a positive step in the company’s product portfolio, potentially enhancing its market position and offering improved treatment options for conditions such as vitamin B6 deficiency and other related ailments.
SSY Group Limited reported a significant decline in its unaudited operating results for the nine months ended September 30, 2025, with turnover decreasing by 31.6% and gross profit dropping by 46.1% compared to the previous year. The company attributes these declines to reduced sales volumes in its key product areas and increased price competition due to expanded volume-based procurement initiatives. The depreciation of the Renminbi against the Hong Kong dollar also impacted financial results, leading to a 56.6% decrease in profit attributable to shareholders.
SSY Group Limited announced that 12 of its products with 14 specifications were selected in the eleventh batch of the National Centralised Medicines Procurement in China. This selection is a significant development for the company, potentially enhancing its market presence and operational growth in the pharmaceutical industry, while also informing shareholders and potential investors of its latest business achievements.
SSY Group Limited has announced the approval of Levamlodipine Besilate Tablets by the National Medical Products Administration of China. This development signifies a strategic advancement in their product offerings, potentially enhancing their market position in the pharmaceutical industry by addressing key health conditions like hypertension and angina.
SSY Group Limited has announced that its Ambroxol Hydrochloride has received approval from China’s National Medical Products Administration to be marketed as a bulk drug. This development signifies a significant advancement in the company’s product offerings, potentially enhancing its market position in the respiratory treatment sector.
SSY Group Limited has announced the approval for drug production and registration of two new chemical drug products by the National Medical Products Administration of China. The newly approved products, Calcium Gluconate and Sodium Chloride Injection and Morinidazole and Sodium Chloride Injection, are expected to enhance the company’s product portfolio, addressing conditions such as acute hypocalcemia and gynecological pelvic inflammatory diseases. This development signifies a strategic advancement in SSY Group’s market positioning, potentially strengthening its competitive edge in the pharmaceutical industry.
SSY Group Limited has announced that its Indocyanine Green product has received approval from China’s National Medical Products Administration for registration as a bulk drug. This development allows the product to be used for diagnosing liver diseases and choroidal angiography, potentially enhancing the company’s market presence and offering new diagnostic solutions.